Abstract
Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine. These suggest that caution should be exercised in patients receiving fludarabine who develop neurological abnormalities, with prompt investigation and if necessary cessation of the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, P., Fearnley, J., Domizio, P. et al. Neurological illness following treatment with fludarabine. Br J Cancer 70, 966–968 (1994). https://doi.org/10.1038/bjc.1994.430
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.430
- Springer Nature Limited
This article is cited by
-
Fludarabine and neurotoxicity in engineered T-cell therapy
Gene Therapy (2018)